May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Visual Function Specific Perimetry to Identify Glaucomatous Vision Loss in the Diagnostic Innovations in Glaucoma Study
P.A. Sample; F.A. Medeiros; L. Racette; J.P. Pascual; C. Boden; L.M. Zangwill; C. Bowd; R.N. Weinreb
Author Affiliations & Notes
  • P.A. Sample
    Hamilton Glaucoma Center, Department of Ophthalmology, UC San Diego, La Jolla, CA
  • F.A. Medeiros
    Hamilton Glaucoma Center, Department of Ophthalmology, UC San Diego, La Jolla, CA
  • L. Racette
    Hamilton Glaucoma Center, Department of Ophthalmology, UC San Diego, La Jolla, CA
  • J.P. Pascual
    Hamilton Glaucoma Center, Department of Ophthalmology, UC San Diego, La Jolla, CA
  • C. Boden
    Hamilton Glaucoma Center, Department of Ophthalmology, UC San Diego, La Jolla, CA
  • L.M. Zangwill
    Hamilton Glaucoma Center, Department of Ophthalmology, UC San Diego, La Jolla, CA
  • C. Bowd
    Hamilton Glaucoma Center, Department of Ophthalmology, UC San Diego, La Jolla, CA
  • R.N. Weinreb
    Hamilton Glaucoma Center, Department of Ophthalmology, UC San Diego, La Jolla, CA
  • Footnotes
    Commercial Relationships  P.A. Sample, Carl Zeiss Meditec, Welch–Allyn, Haag–Streit, F; F.A. Medeiros, Carl Zeiss Meditec, Heidelberg Engineering, F; L. Racette, None; J.P. Pascual, None; C. Boden, None; L.M. Zangwill, Carl Zeiss Meditec Inc., Heidelberg Engineering, F; Heidelberg Engineering, R; C. Bowd, None; R.N. Weinreb, Carl Zeiss Meditec, Heidelberg Engineering, F; Carl Zeiss Meditec, Heidelberg Engineering, R.
  • Footnotes
    Support  NEI EY08208 (PAS), NEI EY11008 (LMZ), Participant retention incentive grants in the form of glaucoma medication at no cost (Alcon Laboratories Inc., Allergan, Pfizer Inc., SANTEN Inc.)
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 3988. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Visual Function Specific Perimetry to Identify Glaucomatous Vision Loss in the Diagnostic Innovations in Glaucoma Study
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      P.A. Sample, F.A. Medeiros, L. Racette, J.P. Pascual, C. Boden, L.M. Zangwill, C. Bowd, R.N. Weinreb; Visual Function Specific Perimetry to Identify Glaucomatous Vision Loss in the Diagnostic Innovations in Glaucoma Study . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3988.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To compare the diagnostic results of three visual function specific perimetric tests and standard automated perimetry and to identify useful parameters from each for determining abnormality.

Methods: : 111 eyes with glaucomatous optic neuropathy (GON), 31 eyes with progressive optic neuropathy (PGON), 53 eyes with ocular hypertension, and 51 healthy eyes were included (N=246). Visual field results were not used to classify eyes. Short–wavelength automated perimetry (SWAP) full threshold, frequency–doubling technology perimetry (FDT) N–30, high pass resolution perimetry (HPRP) and standard automated perimetry (SAP)–SITA were performed. Areas under the receiver operating characteristic (ROC) curves were used to compute sensitivity levels at given specificities. Likelihood ratios and the agreement among tests for abnormality, location, and extent of visual field deficit were assessed.

Results: : ROC analysis: FDT PSD area was larger than HPRP PSD (p=0.020) and FDT TD 5% area was larger than HPRP MD (p=0.004) in the GON group; FDT PD 5% area was larger than SWAP PSD (p=0.020) in the PGON group. At set specificities, FDT yielded higher sensitivities than all other tests for many parameters. The agreement among tests for abnormality was fair to moderate (kappa values ranging from 0.247 to 0.563). When loss was present on more than one test, the area of the visual field affected was the same in 95% (79/83) of eyes. The number of eyes identified and number of abnormal quadrants increased across groups with increasing certainty of glaucoma. Moderate (>3.80) to strong (>6.00) likelihoods of glaucoma were found.

Conclusions: : At equal specificity, no single visual function specific perimetric test was always affected while others remained normal. FDT continues to show promise for diagnosing glaucoma. Use of two tests in combination increased specificity. Several parameters at suggested cut–offs provided good sensitivity and specificity. The likelihood ratios derived for many visual field parameters can be used to assist clinicians in diagnosing glaucoma.

Keywords: perimetry • visual fields 
© 2006, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept